Skip to search boxSkip to navigationSkip to main content

Potential role of sorafenib in the treatment of acute myeloid leukemia

  • Shahram Mori
    ,
  • ,
  • Hagop Kantarjian
    ,
  • Weiguo Zhang
    ,
  • Michael Andreef
    ,
  • Farhad Ravandi(corresponding author)
*Corresponding author for this work
  • University of Texas MD Anderson Cancer Center
Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

The identification of aberrant cellular pathways and dysfunctional molecules important in neoplastic transformation has begun to provide us with a number of targets for drug development. It is likely that many of these agents will be incorporated into our existing treatment strategies that include cytotoxic agents. Sorafenib, a multi-kinase inhibitor has been approved in the United States for the treatment of renal cell carcinoma as well as hepatocellular cancer. Its potential role in hematological malignancies, particularly acute myeloid leukemia (AML) is under evaluation. Here we describe the biological pathways in AML that are the potential targets of sorafenib action and discuss the early clinical data with the agent in solid tumors and AML.

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 2246-2255 (10 pages)

Journal (Volume, Issue Number)

Leukemia and Lymphoma (Volume 49, Issue 12)

Publication milestones

  • Published - 2008

Publication status

Published - 2008

ISSN

1042-8194

Publication IDs

  • Scopus: 57449110921
  • PubMed: 19052971

Publication metrics

Metrics

SciVal
citations
44
Scopus
citations
SciVal
FWCI
1.22
SciVal
Author count
6
SciVal
Paper percentile
87
Fractional count
2
Fractional count
0.33
Fractional count
4
Fractional count
0.67
Fractional count
2
Fractional count
1

PlumX, opens in new tab

Captures
41
Citation count
51

Funding Details

FunderFunding number
NCI
P30CA016672